^
    Back
    Association details:
    Biomarker:SSTR positive
    Cancer:Neuroendocrine Tumor
    Drug:Somatuline Depot (lanreotide prolonged-release subcutaneous) (SSTR agonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ASCO.org
    Title:

    SSAs (octreotide or lanreotide) are recommended for SSTR-positive and/or functional metastatic G1-grade 2 (G2) GI-NETs…

    Published date:
    09/29/2023
    Excerpt:
    SSAs (octreotide or lanreotide) are recommended for SSTR-positive and/or functional metastatic G1-grade 2 (G2) GI-NETs…
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    ESMO.org
    Excerpt:
    SSAs can be recommended as first-line therapy for tumour growth control in advanced, slowly-growing SSTR-positive GI and Pan-NETs up to a Ki-67 of 10% [I,A; ESMO-MCBS v1.1 score: 3] for lanreotide and [I, A; ESMO-MCBS v1.1 score: 2] for octreotide.
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Bronchopulmonary/Thymus Neuroendocrine Tumors…Pancreatic Neuroendocrine Tumors (Well-Differentiated Grade 1/2): Preferred Regimens...Octreotide, LAR or lanreotide (if SSR-positive and/or hormonal symptoms).
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    ESMO 2021
    Title:

    1096O - Lanreotide autogel/depot (LAN) in patients with advanced bronchopulmonary (BP) neuroendocrine tumors (NETs): Results from the phase III SPINET study

    Published date:
    09/13/2021
    Excerpt:
    SPINET evaluated LAN in advanced somatostatin receptor (SSTR)-positive TC and AC BP-NETs…Median (95% CI) PFS in the LAN randomized group was 16.6 (12.8–21.9) months…
    Trial ID:
    SPINET; 2015-004992-62
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients

    Excerpt:
    ...- Patients must have had either a positive somatostatin receptor scintigraphy result or a positive 68Gallium-DOTATATE PET imaging result....
    Trial ID:
    CALM-NET
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    A Retrospective Data Analysis of Therapy With PRRT Combined With Lanreotide Autogel® for Neuroendocrine Tumours

    Excerpt:
    ...- Confirmed presence of Somatostatin Receptors (SSTRs) on all target lesions based on positive SSTR scintigraphy (Octreoscan®/99mTC-tektrotyd) or 68Ga SSTR Positron Emission Tomography-Computerised Tomography (PET/CT) imaging, i.e. Grade ≥2 respectively per the Krenning scale or per the modified Krenning scale...
    Trial ID:
    PRELUDE
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg

    Excerpt:
    ...- Positive somatostatin receptors type 2...
    Trial ID:
    CLARINET FORTE
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours

    Excerpt:
    ...- Positive Somatostatin receptors (SSTR) imaging...
    Trial ID:
    SPINET